Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201733277> ?p ?o ?g. }
- W3201733277 endingPage "969" @default.
- W3201733277 startingPage "956" @default.
- W3201733277 abstract "Biliary tract cancers (cholangiocarcinomas and gallbladder cancers) are increasing in incidence and have a poor prognosis. Most patients present with advanced disease, for which the treatment is palliative chemotherapy. Over the past few years, the genomic landscape of biliary tract cancers has been examined and several targeted therapies have been developed. Molecular targets with clinically meaningful activity include fibroblast growth factor receptor (FGFR), isocitrate dehydrogenase (IDH), RAS-RAF-MEK (MAP2K1)-ERK (MAPK3), HER2 (also known as ERBB2), DNA mismatch repair, and NTRK. Pemigatinib, a FGFR1-3 inhibitor, showed encouraging response rates and survival data as second-line treatment and received US Food and Drug Administration (FDA) approval in April, 2020, for previously treated advanced or metastatic cholangiocarcinoma with FGFR2 gene fusion or rearrangements. Ivosidenib, an IDH1 inhibitor, showed improved progression-free survival versus placebo in second-line treatment in the phase 3 ClarIDHy trial. Early phase trials of dabrafenib plus trametinib (BRAF and MEK inhibition) and zanidatamab (a bispecific HER2-antibody) have yielded encouraging response rates. Immunotherapy has mainly produced responses in tumours with deficient mismatch repair or high microsatellite instability (also known as dMMR or MSI-H) or higher PD-L1 score, or both. However, early phase trials of immunotherapy plus chemotherapy in unselected patient populations appear promising. NTRK inhibitors have also shown promise in early phase trials of NTRK-fusion positive solid tumours, including cholangiocarcinoma. In this Review, we discuss current and emerging therapies for advanced biliary tract cancers, with a focus on molecularly targeted therapy." @default.
- W3201733277 created "2021-10-11" @default.
- W3201733277 creator A5007845498 @default.
- W3201733277 creator A5012936802 @default.
- W3201733277 creator A5019790700 @default.
- W3201733277 date "2021-11-01" @default.
- W3201733277 modified "2023-10-12" @default.
- W3201733277 title "Current and emerging therapies for advanced biliary tract cancers" @default.
- W3201733277 cites W1806572515 @default.
- W3201733277 cites W1846586690 @default.
- W3201733277 cites W1903979702 @default.
- W3201733277 cites W1913865396 @default.
- W3201733277 cites W1974564771 @default.
- W3201733277 cites W1981051246 @default.
- W3201733277 cites W1990350409 @default.
- W3201733277 cites W1990765319 @default.
- W3201733277 cites W1995732721 @default.
- W3201733277 cites W1996138775 @default.
- W3201733277 cites W2012887353 @default.
- W3201733277 cites W2033522521 @default.
- W3201733277 cites W2034958840 @default.
- W3201733277 cites W2052203960 @default.
- W3201733277 cites W2054237682 @default.
- W3201733277 cites W2062138514 @default.
- W3201733277 cites W2063276992 @default.
- W3201733277 cites W2063432158 @default.
- W3201733277 cites W2063515380 @default.
- W3201733277 cites W2065397122 @default.
- W3201733277 cites W2068110847 @default.
- W3201733277 cites W2073597876 @default.
- W3201733277 cites W2096888043 @default.
- W3201733277 cites W2097924418 @default.
- W3201733277 cites W2103198051 @default.
- W3201733277 cites W2103797827 @default.
- W3201733277 cites W2108756633 @default.
- W3201733277 cites W2109269285 @default.
- W3201733277 cites W2113222623 @default.
- W3201733277 cites W2114327118 @default.
- W3201733277 cites W2115261608 @default.
- W3201733277 cites W2121848091 @default.
- W3201733277 cites W2133575075 @default.
- W3201733277 cites W2135849593 @default.
- W3201733277 cites W2136264959 @default.
- W3201733277 cites W2137875447 @default.
- W3201733277 cites W2141042450 @default.
- W3201733277 cites W2154711900 @default.
- W3201733277 cites W2159243852 @default.
- W3201733277 cites W2162445014 @default.
- W3201733277 cites W2168106806 @default.
- W3201733277 cites W2180850028 @default.
- W3201733277 cites W2271127196 @default.
- W3201733277 cites W2276686550 @default.
- W3201733277 cites W2309818502 @default.
- W3201733277 cites W2325613386 @default.
- W3201733277 cites W2408652783 @default.
- W3201733277 cites W2585230893 @default.
- W3201733277 cites W2589049990 @default.
- W3201733277 cites W2598439190 @default.
- W3201733277 cites W2601520864 @default.
- W3201733277 cites W2622499649 @default.
- W3201733277 cites W2724543993 @default.
- W3201733277 cites W2743921188 @default.
- W3201733277 cites W2745824859 @default.
- W3201733277 cites W2754867791 @default.
- W3201733277 cites W2762813296 @default.
- W3201733277 cites W2763492611 @default.
- W3201733277 cites W2769183729 @default.
- W3201733277 cites W2782192099 @default.
- W3201733277 cites W2786714651 @default.
- W3201733277 cites W2790254562 @default.
- W3201733277 cites W2805926640 @default.
- W3201733277 cites W2806800293 @default.
- W3201733277 cites W2887948931 @default.
- W3201733277 cites W2897311709 @default.
- W3201733277 cites W2904444972 @default.
- W3201733277 cites W2916978683 @default.
- W3201733277 cites W2921913890 @default.
- W3201733277 cites W2937317161 @default.
- W3201733277 cites W2945968242 @default.
- W3201733277 cites W2946053006 @default.
- W3201733277 cites W2957765331 @default.
- W3201733277 cites W2959525851 @default.
- W3201733277 cites W2966604567 @default.
- W3201733277 cites W2973596517 @default.
- W3201733277 cites W2977364820 @default.
- W3201733277 cites W2977982707 @default.
- W3201733277 cites W2984293721 @default.
- W3201733277 cites W2984359187 @default.
- W3201733277 cites W2996574710 @default.
- W3201733277 cites W3005207564 @default.
- W3201733277 cites W3010157383 @default.
- W3201733277 cites W3010944770 @default.
- W3201733277 cites W3021696184 @default.
- W3201733277 cites W3024247862 @default.
- W3201733277 cites W3026898345 @default.
- W3201733277 cites W3029098519 @default.
- W3201733277 cites W3049104202 @default.
- W3201733277 cites W3080458669 @default.